Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919969 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Metastatic Anal Cancer
A Phase 2 study of Anal Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 4
- Study locations
NCT02919969: Completed Phase 2 study of Anal Cancer, sponsored by Dana-Farber Cancer Institute.
NCT02919969 is a Phase 2 study of Anal Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 38 participants, below the 578-participant average among 19 other Anal Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02919969, a Phase 2 study of Anal Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab
Primary Outcome
Overall response rate of pembrolizumab in metastatic anal cancer patients will be evaluated per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions. A complete response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-10-11 |
| Est. Completion | 2023-03 |
| Phase | Phase 2 |
What the finished NCT02919969 record still lists
NCT02919969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 578-participant average among 19 other Anal Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Anal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02919969 reports a single indexed study location in Massachusetts, Washington.
Frequently Asked Questions
What is clinical trial NCT02919969 about?
NCT02919969 is a clinical study titled "Pembrolizumab in Metastatic Anal Cancer". This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab
What is the current status of trial NCT02919969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2016-10-11. Estimated completion is 2023-03.
What conditions does trial NCT02919969 study?
This clinical trial studies the following conditions: Anal Cancer.
What interventions are being tested in trial NCT02919969?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02919969?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02919969 being conducted?
This trial has 4 study locations across Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02919969's enrollment target sits among peer trials
38 12th of 19 higher than 8 of 19 other Anal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
RECRUITING · Phase 2
-
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
ACTIVE NOT RECRUITING · Phase 2
-
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
COMPLETED · Phase 2
-
Assessing THE GAY Male Experience With Anal Cancer Prevention Strategies
RECRUITING
-
Self-sampling to Optimize Anal Lesion Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI